In the Field
One theme that ran through a recent SAS USA workshop for students at Rockefeller University was the idea that public engagement should be regarded as a duty, not a hobby for scientists.
Of the 13,327 registered trials completed between January 1, 2008 and August 31, 2012 that likely fell under the FDAAA reporting requirements, the results of 62 percent were missing as of August 31, 2012.
Jennifer Miller, Ph.D., a bioethicist at New York University came up with a way to evaluate the transparency of pharmaceutical companies. She calls it the Good Pharma Scorecard.